Y-mabs to host key opinion leader webinar on danyelza® (naxitamab-gqgk) frontline and hits data in high-risk neuroblastoma

New york, sept. 10, 2021 (globe newswire) -- y-mabs therapeutics, inc. (the "company" or "y-mabs") (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it will host a key opinion leader ("kol") webinar on danyelza frontline and hits data in high-risk neuroblastoma on thursday, september 23, 2021 at 12 p.m. et.
YMAB Ratings Summary
YMAB Quant Ranking